Journal
MOLECULAR THERAPY
Volume 3, Issue 4, Pages 613-622Publisher
ACADEMIC PRESS INC
DOI: 10.1006/mthe.2001.0288
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL 51751, HL 59314] Funding Source: Medline
Ask authors/readers for more resources
Adenoviral vectors are attractive for the delivery of transgenes into mammalian cells because of their efficient transduction, high titer, and stability. The major concerns with using El-deleted adenoviral vectors in gene therapy are the pathogenic potential of the virus backbone and the leaky viral protein synthesis that leads to host immune responses and a short duration of transgene expression. Helper-dependent (HD) adenoviral vectors that are devoid of all viral protein-coding sequences have significantly increased the safety and reduced the immunogenicity of these vectors. Currently available HD vectors depend on an El-deleted adenovirus as a helper to provide viral proteins in trans. As a consequence, contamination with helper virus cannot be avoided in the HD vector preparation though it can be decreased to 0.01% using a Cre/IoxP mechanism. Since the presence of El-deleted helper virus may have substantial unwanted effects, we have developed a new Cre-expressing cell line based on an E1- and E2a-complementing cell. This new cell line can efficiently cleave the packaging region in the helper virus genome. We have also developed an El and E2a double-deleted helper virus. By using the CreE cell with the helper virus deleted in both the El and the E2a genes it may be possible to further improve the safety of the vectors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available